Table 2.
Survival analysis and group differences of rCC and lCC
| rCC (n = 230) | p-value (log-rank) | lCC (n = 187) | p-value (log-rank) | p-value (χ2/t-test) | |
|---|---|---|---|---|---|
| Age (years) | 0.286 | < 0.001 | 0.256 | ||
| < 65 | 81 (35.2%) | 76 (40.6%) | |||
| ≥ 65 | 149 (64.8%) | 111 (59.4%) | |||
| Mean | 68.0 ± 0.8 | 65.6 ± 1.0 | 0.066 | ||
| Sex | 0.359 | 0.003 | < 0.001 | ||
| Female | 112 (48.7%) | 58 (31.0%) | |||
| Male | 118 (51.3%) | 129 (69.0%) | |||
| ASA-Score | < 0.001 | < 0.001 | 0.138 | ||
| I | 14 (6.1%) | 23 (12.3%) | |||
| II | 128 (55.7%) | 97 (51.9%) | |||
| III | 86 (37.4%) | 64 (34.2%) | |||
| IV | 2 (0.9%) | 3 (1.6%) | |||
| BMI (kg*m−2) | 0.313 | 0.748 | 0.318 | ||
| ≤ 18.4 | 11 (4.8%) | 3 (1.6%) | |||
| 18.5–24.9 | 99 (43.0%) | 88 (47.1%) | |||
| 25.0–29.9 | 79 (34.3%) | 62 (33.2%) | |||
| ≥ 30 | 41 (17.8%) | 34 (18.2%) | |||
| Mean | 26.2 ± 0.4 | 26.2 ± 0.3 | 0.977 | ||
| CEA (µg/l)*1 | < 0.001 | < 0.001 | 0.985 | ||
| 0–5.0 | 153 (67.4%) | 121 (66.1%) | |||
| 5.1–20.0 | 45 (19.8%) | 37 (20.2%) | |||
| 20.1–100.0 | 20 (8.8%) | 18 (9.8%) | |||
| > 100.0 | 9 (4.0%) | 7 (3.8%) | |||
| Mean | 56.6 ± 26.5 | 69.4 ± 37.2 | 0.775 | ||
| Tumor entity | 0.987 | 0.054 | 0.027 | ||
| NST | 98 (42.6%) | 86 (46.0%) | |||
| Tubular | 76 (33.0%) | 76 (40.6%) | |||
| Mucinous | 44 (19.1%) | 22 (11.8%) | |||
| Others | 12 (5.2%) | 3 (1.6%) | |||
| pT-stage | < 0.001 | 0.014 | 0.065 | ||
| Tis/T1 | 25 (10.9%) | 23 (12.3%) | |||
| T2 | 46 (20.0%) | 30 (16.0%) | |||
| T3 | 108 (47.0%) | 108 (57.8%) | |||
| T4a/b | 51 (22.2%) | 26 (13.9%) | |||
| pN-stage*2 | < 0.001 | 0.175 | 0.012 | ||
| N0 | 131 (57.2%) | 108 (57.8%) | |||
| N1a/ N1b/N1c | 27 (11.8%)/26 (11.4%)/7 (3.1%) | 11 (5.9%)/25 (13.4%)/19 (10.2%) | |||
| N2a/N2b | 14 (6.1%)/24 (10.5%) | 12 (6.4%)/12 (6.4%) | |||
| pM-stage | < 0.001 | < 0.001 | 0.579 | ||
| M0 | 180 (78.3%) | 150 (80.2%) | |||
| M1a/M1b/M1c | 36 (15.7%)/7 (3.0%)/7 (3.0%) | 30 (16.0%)/5 (2.7%)/2 (1.1%) | |||
| Lymph node ratio*3 | < 0.001 | 0.054 | 0.726 | ||
| 0.0 | 138 (60.5%) | 121 (65.1%) | |||
| 0.01–0.29 | 60 (26.3%) | 46 (24.7%) | |||
| 0.30–0.59 | 19 (8.3%) | 13 (7.0%) | |||
| 0.60–1.0 | 11 (4.8%) | 6 (3.2%) | |||
| Grade*4 | 0.001 | 0.026 | 0.043 | ||
| G1 | 13 (5.7%) | 7 (3.8%) | |||
| G2 | 146 (63.8%) | 142 (76.3%) | |||
| G3 | 69 (30.1%) | 37 (19.9%) | |||
| G4 | 1 (0.4%) | ||||
| Lymphangioinvasion | 0.004 | 0.393 | 0.690 | ||
| L0 | 172 (74.8%) | 143 (76.5%) | |||
| L1 | 58 (25.2%) | 44 (23.5%) | |||
| Venous invasion | 0.001 | 0.001 | 0.207 | ||
| V0 | 204 (88.7%) | 158 (84.5%) | |||
| V1 | 26 (11.3%) | 29 (15.5%) | |||
| Perineural invasion | 0.083 | 0.526 | 0.981 | ||
| Pn0 | 225 (97.8%) | 183 (97.9%) | |||
| Pn1 | 5 (2.2%) | 4 (2.1%) | |||
| R-stage | 0.064 | 0.006 | 0.485 | ||
| R0 | 221 (96.1%) | 182 (97.3%) | |||
| R1 | 9 (3.9%) | 5 (2.7%) | |||
| Microsatellite instability*5 | 0.449 | 0.724 | < 0.001 | ||
| MSS | 118 (76.1%) | 113 (95.0%) | |||
| MSI | 37 (23.9%) | 6 (5.0%) | |||
| Type of operation | 0.091 | < 0.001 | 0.140 | ||
| Laparoscopy | 79 (34.3%) | 77 (41.2%) | |||
| Laparotomy | 127 (55.2%) | 99 (52.9%) | |||
| Conversion | 24 (10.4%) | 11 (5.9%) | |||
| Clavien-Dindo*6 | 0.113 | 0.001 | 0.687 | ||
| 0–II | 155 (69.2%) | 130 (71.0%) | |||
| III–IV | 69 (30.8%) | 53 (29.0%) | |||
| Chemotherapy (adjuvant) | 79 (34.3%) | 0.394 | 60 (32.1%) | 0.908 | 0.626 |
rCC right-sided colon cancer, lCC left-sided colon cancer, ASA American Society of Anesthesiologists, BMI body mass index, CEA carcinoembryonic antigen, NST no special type, MSS microsatellite stable, MSI microsatellite instable, Clavien-Dindo Clavien-Dindo classification of surgical complications
*1n = 227 (rCC), n = 183 (lCC); *2n = 229 (rCC); *3n = 228 (rCC), n = 186 (lCC); *4n = 229 (rCC), n = 186 (lCC); *5n = 155 (rCC), n = 119 (lCC); *6n = 224 (rCC), n = 183 (lCC)